Cantor Fitzgerald’s Post

In this recent news segment on weight management medications, Dr. Anthony Auriemma, an obesity medicine specialist from Ascension Medical Group Illinois Weight Loss Solutions discusses the obesity “pandemic” and various treatment options. The segment discusses the price challenges of GLP-1 therapies and highlights the results and lower out-of-pocket costs for patients with an oral, VIVUS weight-management medication. It notes that patient interest in more affordable treatment options is reinvigorating interest in these established, proven medications. Watch the news segment online at: https://lnkd.in/eQScbQCr VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to patients globally. To learn more about our work in this area please visit VIVUS.com. #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

Based on a recent NEJM double-blind, randomized, placebo-controlled trial, our new Essential Knowledge Update (EKU) Hot Topic explores whether a 2.4-mg dose of semaglutide would be superior to placebo as an adjunct to lifestyle modifications in reducing body weight and pain related to knee OA in participants with obesity, clinical and radiologic diagnosis of moderate knee OA, and pain that is at least moderately severe. Read our new EKU Hot Topic to learn about this topic further. ⤵️ 🔗 https://lnkd.in/ev88Kjus

Announcing our Annual Spring Conference! Join us for Endocrine Typing: Connecting the Dots Between Toxin Load, Weight Loss Resistance, and Hormonal Dysfunction. 📍 Chicago, Illinois 📅 April 19th & 20th, 2024 The complex interactions of endocrine disorders, hormone dysfunction, and cardiometabolic processes are resulting in high rates of obesity, fatigue, and devastating chronic illness. The finest minds on these topics gather this April to fully explore the synergies of this perfect storm and offer strategies for diagnosis, prevention, and remediation. Practical information will be given about the tools of biodetoxification, methods of diagnoses (lab assessments, metabotypes, endotypes, advanced clinical assessment), and specific protocols for clients. Healthcare practitioners will not want to miss this! Learn more here: https://lnkd.in/giYkYv_B P.S. Register soon! Tickets are going fast! #plmi #personalizedlifestylemedicine #integrativemedicine #functionalmedicine #holistichealth #naturalmedicine #practitioners #endocrinetyping #toxin #weightloss #hormonaldysfunction #chicago #cardiometabolic #medicine #doctos #naturopath #clinicians #healthconference

Join our Annual Spring Conference to examine Endocrine Typing: Connecting the Dots Between Toxin Load, Weight Loss Resistance, and Hormonal Dysfunction. 📍 Chicago, Illinois 📅 April 19th & 20th, 2024 Rising obesity, fatigue and chronic illnesses are pointing to the nexus of endocrine dysfunction, hormone imbalances, and cardiometabolic processes. Medical experts, doctors, and naturopaths assemble this April to delve into these mechanisms as well as present strategies for diagnosis, prevention, and remediation. Healthcare practitioners will appreciate the conference presentations analyzing the tools of biodetoxification, methods of diagnoses (lab assessments, metabotypes, endotypes, advanced clinical assessment), and specific protocols for clients. Read the entire lineup of exciting topics at: https://lnkd.in/giYkYv_B P.S. Register soon! Tickets are going fast! #plmi #personalizedlifestylemedicine #integrativemedicine #functionalmedicine #holistichealth #naturalmedicine #practitioners #endocrinetyping #toxin #weightloss #hormonaldysfunction #chicago #cardiometabolic #medicine #doctos #naturopath #clinicians #healthconference

According to a study published in Diabetes Care, a journal of the American Diabetes Association, pancreas size can better predict disease progression of type 1 diabetes than MRI imaging or glucose testing alone. “If we can better predict the progression to stage 3, our hope is that we can better identify and apply therapies to slow or even stop the advance of the disease, even before diagnosis,” said lead author Jack Virostko, PhD and assistant professor of Diagnostic Medicine in the Dell Medical School at The University of Texas at Austin. Check out this Managed Healthcare Executive article to learn more about the study: https://hubs.la/Q02Dq5h60 #DigitalDiagnostics #LumineticsCore #Diabetes #Healthcare

In JAMA, Journal of the American Medical Association, physicians from Stanford and Mass General Hospital emphasize the importance of maintaining a healthy balance between lean and fat during weight loss. “Excessive loss of lean muscle mass can cause sarcopenic obesity, which is associated with functional decline and increased mortality. As such, while visceral fat loss is beneficial, it should be accompanied by preservation of or an increase in muscle mass for ideal health outcomes.” BioAge’s lead compound azelaprag is an oral drug with the potential to significantly increase weight loss and improve body composition in patients on incretin therapy for obesity. https://lnkd.in/gv2_QFYe

Understanding Obesity: Treatments and Patient Experiences This NEJM video offers insights into obesity, highlighting the latest surgical and medical treatments for weight loss. Experts discuss the science behind these therapies, while patients share their personal experiences with obesity, addressing the bias and stigma they face. The video emphasizes how medical advancements are helping patients manage their weight more effectively. #ObesityTreatment #MedicalTherapies #WeightLoss #ObesityBias #PatientExperience Credits: NEJM Group Ania Jastreboff, MD, PhD Sriram Machineni Louis Aronne

Don’t miss out! Enroll today in the "Practical Strategies for Applying Evidence and Patient Perspectives to Improve Obesity Management" program by Clinical Care Options and supported by Eli Lilly and Company. Discover expert insights on reducing complications, personalizing treatment plans, and fostering long-term weight loss success. Learn more at https://bit.ly/45u89mE #ObesityTreatment #ObesityManagement

GLP-1s can be amazing...for some patients. But, how do researchers, payers, clinicians, and patients know if they are right for them? Would certain patient populations be better suited for a different drug or for a procedure? Or perhaps both? Join panelists as they explore the use of data, technology, and experience to start answering questions around personalized treatment pathways in obesity.

Update: this article is now open access: https://lnkd.in/e6NmtdpP Learn more about how RDNs make a large impact in obesity care! A recent article in JAND "RDNs Lead in Obesity Care, including with Incretin-Based Therapies" discusses an RDN's role in obesity care with MNT, medication management, and collaboration with the interdisciplinary care team. For more resources on this topic, see the Academy’s statement on the use of obesity medications, online report and webinar series.